Zoptarelin doxorubicin

• CAS Number:

  139570-93-7

• UNSPSC Description:

  Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro[1].

• Target Antigen:

  GnRH Receptor; Peptide-Drug Conjugate (PDC)

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/zoptarelin-doxorubicin.html

• Solubility:

  H2O

• Smiles:

  OC1=C2C(C(C3=C(OC)C=CC=C3C2=O)=O)=C(O)C([C@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N)=C1C[C@](O)(C4)C(COC(CCCC(NCCCC[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(NCC(N)=O)=O)=O)=O)=O)NC([C@@H](NC([C@H](CO)NC([C@@H](NC([C@@H](NC([C@H]7NC(CC7)=O)=O)CC8=CN=CN8)=O)CC9=CNC%10=CC=CC=C9%10)=O)=O)CC%11=CC=C(C=C%11)O)=O)=O)=O)=O

• Molecular Weight:

  1893.01

• References & Citations:

  [1]Jaszberenyi M, et al. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Oncotarget. 2013 Mar;4(3):422-32.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3